35543-30-7

Upstream product

• 621-23-8 1,2,3-trimethoxybenzene 
• 107-14-2 chloroacetonitrile 

Downstream Products

• 23111-18-4 3-phenyl-N-[4-(2,4,6-trimethoxy-phenyl)-thiazol-2-yl]-acrylamide 
• 23111-51-5 N-[4-(2,4,6-trimethoxy-phenyl)-thiazol-2-yl]-propionamide 
• 23111-15-1 3,4,5-trimethoxy-N-[4-(2,4,6-trimethoxy-phenyl)-thiazol-2-yl]-benzamide 
• 23111-22-0 2-(4-chloro-phenoxy)-N-[4-(2,4,6-trimethoxy-phenyl)-thiazol-2-yl]-acetamide 
• 23111-20-8 N-[4-(2,4,6-trimethoxy-phenyl)-thiazol-2-yl]-benzamide 
• 23111-49-1 N-[4-(2,4,6-trimethoxy-phenyl)-thiazol-2-yl]-acetamide 
• 4783-96-4 2-morpholino-1-(2,4,6-trimethoxyphenyl)ethanone 
• 107520-80-9 2,3-epoxy-3-(3-nitro-phenyl)-1-(2,4,6-trimethoxy-phenyl)-propan-1-one 
• 108063-17-8 2-chloro-3-hydroxy-3-(3-nitro-phenyl)-1-(2,4,6-trimethoxy-phenyl)-propan-1-one 
• 100613-63-6 2-acetoxy-1-(2,4,6-trimethoxy-phenyl)-ethanone 

Relevant academic research and scientific papers

A Novel Parkinson's Disease Drug Candidate with Potent Anti-neuroinflammatory Effects through the Src Signaling Pathway

Numerous drug treatments are available for Parkinson's disease (PD), an age-related neurodegenerative disease, but most cause serious side effects. Therefore, novel therapeutic strategies that halt disease progression and allow for long-term administration are urgently needed. Neuroinflammation critically contributes to the pathogenesis of PD. Here, we report the discovery and optimization of phloroglucinol derivatives, a novel class of anti-neuroinflammatory compounds. Structural modifications of the hit compound 3-methyl-1-(2,4,6-trihydroxyphenyl)butan-1-one produced 43 derivatives, including a preclinical candidate (compound 21), that exhibited potent in vitro anti-neuroinflammatory effects, good blood-brain barrier penetration, and desirable safety margins in mice at a median lethal dose (LD50) >5000 mg/kg. Its in vivo efficacy was demonstrated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)- and MPTP/probenecid (prob)-induced subacute and chronic PD models, respectively, and α-synuclein transgenic mice. Mechanistic studies revealed neuroinflammation inhibition by targeting Src/phosphatase and tensin homologue deleted on chromosome 10 (PTEN)/Akt signaling might be promising. We highlighted the potential usefulness of phloroglucinol derivatives in PD treatment.